Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Among the compounds prepared at this stage the cyclopropylme
2021-12-17

Among the compounds prepared at this stage, the cyclopropylmethylenoxy analogue attracted our most attention since it demonstrated particularly good in vitro potency at GlyT1 (16nM), no activity at the GlyT2 isoform up to the highest concentration tested (30μM), good physical properties with moderat
-
In the present study we
2021-12-17

In the present study, we characterized the expression of glucose transporters in the developing and adult mouse lens and showed that GLUT1 is the primary transporter expressed in the lens epithelium. We found that mice with a homozygous deletion of Slc2a1 from the lens epithelium developed cataracts
-
Despite potent biological actions the native hormone undergo
2021-12-17

Despite potent biological actions, the native hormone undergoes degradation by the enzyme dipeptidylpeptidase-IV (DPP-IV) [17] and is rapidly cleared from the bloodstream by renal filtration [18]. One such approach to prolong the biological half-life of GIP is through conjugation with a polyethylene
-
br Competing interests br Acknowledgements br Introduction
2021-12-17

Competing interests Acknowledgements Introduction - Factors Regulating Glucose Tolerance Strictly speaking, the incretin effect refers to the amplification of insulin secretion, which occurs when Cy5 hydrazide (non-sulfonated) is taken in orally as compared to infused intravenously [1]. No
-
EI1 Analgesic activity was evaluated by measuring
2021-12-16

Analgesic activity was evaluated by measuring tail flick latencies to the immersion of rat’s tail in water, maintained at ∼51°C [18] after recovery from anesthesia. Typically, rats were immobilized inside a restrainer, leaving only the tail exposed, which was then immersed into the hot water bath, a
-
br Role of FPRs in regulating the inflammatory
2021-12-16

Role of FPRs in regulating the inflammatory response Annexin I is a glucocorticoid-regulated protein possessing both pro- and anti-inflammatory activity that might be mediated, in part, by FPR activation [35]. Expressed in a variety of cell types, annexin I is particularly abundant in neutrophils
-
Species specificity of small molecular GPR agonists have bee
2021-12-16

Species specificity of small molecular GPR40 agonists have been reported by Takeda scientist. In the binding pocket of TM5, a Leu186 in human GPR40/FFA1 is replaced with Phe in rat, resulting in dramatic inter-species GPR40 activity discrepancy in certain scaffolds of small molecular GPR40 agonists.
-
Fluconazole br PEPCK This enzyme decarboxylates and then pho
2021-12-16

PEPCK This enzyme decarboxylates and then phosphorylates oxaloacetate to form phosphoenolpyruvate (PEP) in the second step of gluconeogenesis after the carboxylation of pyruvate catalyzed by PC. PEPCK1 (PEPCK-C, encoded by the PCK1 gene) and PEPCK2 (PEPCK-M, encoded by the PCK2 gene) are two isof
-
br Materials methods br Results
2021-12-16

Materials & methods Results FAS c.-671AA, AG and GG genotypes and A and G pramiracetam frequencies were similar in both patients with FMF and healthy control groups, and no significant difference was found (P>0.05, Table 1). The frequency of TC genotype in FASLG in the healthy controls was si
-
br Although there are growing bodies of research dealing wit
2021-12-16

Although there are growing bodies of research dealing with diverse non-imidazole based compounds, they are not free from obstacles in their development pipeline and hence the design of these compounds is complicated by various factors briefly discussed below. One of the problems in designing H3R a
-
Initial experiments confirmed that RBC
2021-12-16

Initial experiments confirmed that RBC8 effectively inhibited both RalA and RalB activation in an identical, dose-dependent manner following platelet stimulation with the GPVI-specific ligand, CRP (Fig. 1Ai). Non-specific, upper bands were observed when immunoblotting for activated RalB, with the sp
-
Based on the results of compound appeared to
2021-12-16

Based on the results of , ARCA EGFP mRNA appeared to have the best overall profile, so our efforts were then devoted to using 5-(-propyl)pyrimidine as the right-hand nitrogen attachment to optimize the R group of (). Analog was synthesized using the reaction conditions from , while analogs and
-
br Materials and methods br Results and discussion
2021-12-16

Materials and methods Results and discussion Conclusion A new label-free targeted methodology using two-step fractionation coupled with conventional microflow LC-MS/MS was developed and validated to profile 54 selected clinically relevant human plasma glycoproteins. The developed method has
-
Anderson et al reported a markedly decreased
2021-12-16

Anderson et al reported fluvastatin sale markedly decreased maladaptive behavior traits of the VABS maladaptive behavior score after using EAA (Equine Assisted Activities) (F(1,11) = 5.65, = 5.65, (F(1,11) = 5.19, p = 0.04). However, the results of other EQ/SQ parts and of the VABS correlated with
-
To confirm the in vitro findings atorvastatin or
2021-12-16

To confirm the in vitro findings, atorvastatin or pravastatin was given to C57BL6/J mice fed with high fat diet. Doses of atorvastatin were set to be 6 mg/kg and 12 mg/kg, which were within clinical therapeutic doses. The results revealed that treatment of atorvastatin but not pravastatin impaired g
16039 records 547/1070 page Previous Next First page 上5页 546547548549550 下5页 Last page